?? Dentons has announced the cooptation of Julien Le Guyader as partner in the Life Sciences Group of the Paris Office. Le Guyader has been a part of ?? Dentons since 2014.
https://european-biotechnology.com/wp-content/uploads/2024/04/julien-le-guyader.jpg472420h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-03-21 16:52:392024-04-02 14:36:05Dentons: All about taxes
Scottish and Canadian researchers have identified a protein essential for the toxoplasmosis parasite to be transmitted. Targeting it might give rise to new treatments other parasitic diseases like malaria.
Belgian clinical-stage immunotherapy developer Asit biotech has appointed Gerd Zettlmeissl as its new Chairman of the Board. Zettlmeissl has been independent director of the company since 2011.
British inhaled anti-infectives specialist Pulmocide has bagged US$30.4m (€28.8m) from new and existing investors to bring its anti-RSV and anti-aspergillosis compounds into clinical testing.
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-03-20 10:18:592017-03-20 10:18:59Pulmocide raises £25m in Series B round
The investment groups Q-Growth Fund and Biolty purchased the majority of the Valencian biotechnology company Institute of Genomic Medicine (Imegen) for €10m.
British Cell Medica has closed a 60£ (€68,8m) Series C financing to advance its pipeline of virus-specific Natural Killer T (NKT) cells in oncology and viral infection.
https://european-biotechnology.com/wp-content/uploads/2024/04/Cellmedica.jpg363580Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2017-03-16 09:28:012017-03-16 09:28:01Cell Medica bags €68,8 in Series C
According to main investor Sofinnova Partners, the Euronext IPO of Avantium, the front runner in renewable chemistry, was oversubscribed multiple times resulting in a market capitalisation of €277m.
Transgene has started Phase II efficacy testing of its therapeutic cancer vaccine TG4010 and Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) in non-squamous non-small cell lung cancer (NSCLC).
Belgian cell therapeutics specialist TiGenix NV announced positive top-line one-year results from its CAREMI stem cell study in acute myocardial infarction.
There’s no way around it: renewables are the future, Matti Heikkilä believes. European Biotechnology talked to the CTO of Finnish bioeconomy company MetGen about what bio-based products need to bring to the table to usurp their fossil-based counterparts.
https://european-biotechnology.com/wp-content/uploads/2024/04/matti-heikkilae.jpg450800h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2017-03-10 11:31:002017-03-10 11:31:00A clear path ahead for the bioeconomy
Dentons: All about taxes
AppointmentsToxoplasmosis: novel target to prevent transmission
Latest NewsScottish and Canadian researchers have identified a protein essential for the toxoplasmosis parasite to be transmitted. Targeting it might give rise to new treatments other parasitic diseases like malaria.
Asit biotech: Expertise in vaccines
AppointmentsPulmocide raises £25m in Series B round
Latest NewsBritish inhaled anti-infectives specialist Pulmocide has bagged US$30.4m (€28.8m) from new and existing investors to bring its anti-RSV and anti-aspergillosis compounds into clinical testing.
Investors purchase Imegen
Latest NewsThe investment groups Q-Growth Fund and Biolty purchased the majority of the Valencian biotechnology company Institute of Genomic Medicine (Imegen) for €10m.
Cell Medica bags €68,8 in Series C
Latest NewsBritish Cell Medica has closed a 60£ (€68,8m) Series C financing to advance its pipeline of virus-specific Natural Killer T (NKT) cells in oncology and viral infection.
Avantium raised €103m in oversubscribed IPO
Latest NewsAccording to main investor Sofinnova Partners, the Euronext IPO of Avantium, the front runner in renewable chemistry, was oversubscribed multiple times resulting in a market capitalisation of €277m.
NSCLC: Transgene launches cancer combo tests
Latest NewsTransgene has started Phase II efficacy testing of its therapeutic cancer vaccine TG4010 and Bristol-Myers Squibb’s checkpoint inhibitor Opdivo (nivolumab) in non-squamous non-small cell lung cancer (NSCLC).
Allogenic stem cell transplant safe in heart infarction patients
Latest NewsBelgian cell therapeutics specialist TiGenix NV announced positive top-line one-year results from its CAREMI stem cell study in acute myocardial infarction.
A clear path ahead for the bioeconomy
Opinion